开拓药业(09939.HK)与仁东医学、惠每健康签署战略合作协议 打造诊疗一体化平台
开拓药业(09939.HK)与仁东医学、惠每健康签署战略合作框架协议,三方将推进战略合作,旨在打造诊疗一体化平台和以患者为中心的闭环营销体系,积极推动前列腺癌、乳腺癌等肿瘤患者的伴随诊断,以及大数据分析、患者管理、新药研发和数字化营销等一体化平台建设。
公司指,仁东医学是中国领先的基因检测整体解决方案供应商,是国内泌尿系统肿瘤精准检测的市场领导者;惠每健康是Mayo Clinic和高瓴资本在中国的合资公司惠每医疗集团的子公司,专注於基於SaaS平台提供一站式赋能学术营销解决方案,致力於成为中国医疗数字化营销领先者。此次合作以前列腺癌领域开启,後续在乳腺癌等多癌症领域铺开,实现三方共同的战略延伸。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.